ARTICLE | Clinical News

Arzerra ofatumumab: Phase III started

October 13, 2014 7:00 AM UTC

GlaxoSmithKline's Stiefel dermatology business began the double-blind, placebo-controlled, international Phase III OPV116910 trial to compare 20 mg subcutaneous ofatumumab every 4 weeks plus oral steroids vs. oral steroids alone for 56 weeks in about 136 patients with active pemphigus vulgaris. Patients will undergo a scheduled gradual reduction in steroid use. ...